SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
PURSUANT
TO RULE 13a-16 OR 15d-16 OF THE
SECURITIES
EXCHANGE ACT OF 1934
Dated
May 2, 2005
IMI
International Medical Innovations Inc.
Commission
File Number 1-31360
615-4211
Yonge Street
Toronto,
Ontario M2P 2A9
CANADA
(Address
of Principal Executive Offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
"Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- ________
IMI
International Medical Innovations Inc.
Form
6-K
On
May 2, 2005, the
Corporation issued a press release announcing that patients with elevated skin
sterol and a high
Framingham global risk score have a significantly higher risk of multivessel
disease (narrowing in two or more coronary vessels), according to data presented
on Saturday at the 6th Annual
Conference on Arteriosclerosis, Thrombosis and Vascular Biology, in Washington,
DC. The information contained in the press release is incorporated herein by
reference and filed as Exhibit 99.1.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this Report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| |
IMI
International Medical Innovations Inc. |
| |
|
|
| |
|
|
| |
By: |
/s/
Ronald G. Hosking |
| |
|
Ronald
G. Hosking |
| |
|
Vice
President and Chief Financial Officer |
Date:
May 2, 2005
EXHIBIT
INDEX
|
Exhibit |
|
|
|
Number |
|
Description |
|
99.1 |
|
The
Registrant’s Press Release Dated
May
2, 2005 |